The FDA has requested more time to decide whether to approve Ustekinumab , a monoclonal antibody of Johnson & Johnson for the treatment of psoriasis, going against the advice of its experts. ( xagenasalute.it )
Thursday, January 22, 2009
Dance Costumes Contemporary
New drugs: the FDA is more cautious
The FDA has requested more time to decide whether to approve Ustekinumab , a monoclonal antibody of Johnson & Johnson for the treatment of psoriasis, going against the advice of its experts. ( xagenasalute.it )
The FDA has requested more time to decide whether to approve Ustekinumab , a monoclonal antibody of Johnson & Johnson for the treatment of psoriasis, going against the advice of its experts. ( xagenasalute.it )
Wednesday, January 21, 2009
Tie With Untucked Shirt
Un nuovo topico per la psoriasi: IP10:C8
E 'match the phase II for a new topical medication that would act at the same time inhibiting the dipeptidyl peptidase IV and aminopeptidase N.
The drug, whose acronym is provisional IP10: C8, deriva da un brevetto della tedesca Immune Technologies and Medicine ( IMTM ) chiamato Peptidase Targeted Immune Regulation (PETIR™)
PETIR™ therapy involves the combined inhibition of two peptidases that are chiefly responsible for immune response (DPIV and APN families), by using dual inhibitors. PETIR™ is realized by the use of single NCEs that combine both inhibitory modes of action into a single substance.
This completely new approach acts both, on central regulatory mechanisms of the immune system, by activation of regulatory T cells and direct inhibition of activation and proliferation of activated immune effector cells. This holds true for TH1 as well as TH2 mediated immune responses. 
E 'match the phase II for a new topical medication that would act at the same time inhibiting the dipeptidyl peptidase IV and aminopeptidase N.
The drug, whose acronym is provisional IP10: C8, deriva da un brevetto della tedesca Immune Technologies and Medicine ( IMTM ) chiamato Peptidase Targeted Immune Regulation (PETIR™)
PETIR™ therapy involves the combined inhibition of two peptidases that are chiefly responsible for immune response (DPIV and APN families), by using dual inhibitors. PETIR™ is realized by the use of single NCEs that combine both inhibitory modes of action into a single substance.
This completely new approach acts both, on central regulatory mechanisms of the immune system, by activation of regulatory T cells and direct inhibition of activation and proliferation of activated immune effector cells. This holds true for TH1 as well as TH2 mediated immune responses.
Sunday, January 18, 2009
1985-91 Corvette Muffler Eliminator
Un nuovo topico per la psoriasi: bimosiamose
The German Revotar Biopharmaceuticals AG has started a trial Phase II of its Bimosiamose cream 5%. The cream was safe and well tolerated by study Phase I. The
Bimosiamose is a new potent synthetic inhibitor of all selectins (P, E, L), molecules that are fundamental in nell'attachment leukocyte rolling and migration during vascular endothelium at sites of inflammation.
Bibliography:
Bimosiamose AND psoriasis on PubMed 
The German Revotar Biopharmaceuticals AG has started a trial Phase II of its Bimosiamose cream 5%. The cream was safe and well tolerated by study Phase I. The
Bimosiamose is a new potent synthetic inhibitor of all selectins (P, E, L), molecules that are fundamental in nell'attachment leukocyte rolling and migration during vascular endothelium at sites of inflammation.
Bibliography:
Bimosiamose AND psoriasis on PubMed
Ladies Housecoats In Canada
Un nuovo indice per misurare la QoL
E 'trial started a to create and validate a new index called CQOL (Chronic Quality of Life) that explores habits, career and life choices of psoriasis patients.
The hypothesis of the authors is that patients with the diagnosis (and therapy) are made at a young age may have a worse quality of life in the long run. 
E 'trial started a to create and validate a new index called CQOL (Chronic Quality of Life) that explores habits, career and life choices of psoriasis patients.
The hypothesis of the authors is that patients with the diagnosis (and therapy) are made at a young age may have a worse quality of life in the long run.
Subscribe to:
Posts (Atom)